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Cardiovascular disease is a major cause of morbidity and mortality in New Zealand. Elucidating 
its pathogenesis will help us better treat those who are affected by it. One protein that has 
been implicated in cardiovascular pathology is Calcium (Ca2+)/Calmodulin-dependent protein 
Kinase II (CaMKII). As its name suggests, it is activated by Ca2+-bound calmodulin. In a healthy 
heart, CaMKII plays a role in regulating Ca2+-handling proteins in the cardiomyocyte, such as 
Ryanodine Receptor and Phospholamban. CaMKII has the ability to become autonomously 
activated so that it can exert its effects even when the Ca2+ concentration decreases. 
However, when CaMKII is activated when it does not need to be, it can have pathological 
effects. It can be activated pathologically by hyperglycemia, oxidative stress and 
hyperadrenergic states, all of which are seen in cardiovascular pathology such as heart failure 
or diabetic cardiomyopathy. Alpha-adrenergic receptor signaling can also activate CaMKII, but 
little is known about the effects of alpha-adrenergic stimulation on the heart.  
The aim of this project was the determine the functional effects of the alpha-adrenergic 
agonist Methoxamine on isolated wild-type mouse hearts, and in isolated CaMKII knockout 
mouse heart, in incremental doses to observe differences in the responses between the two 
groups to determine the role of CaMKII in the functional response to alpha-adrenergic 
stimulus in the heart.  
The technique used to address these aims was the isolated heart set-up, which is also known 
as the Langendorff setup. The mouse hearts were surgically removed from the animal, with 
part of the aorta intact, and placed in an arresting buffer with a high potassium chloride 
concentration to ionically arrest the heart. The heart was then cannulated via the aorta, and 
perfused with a Krebs-Henseleit Buffer (KHB) that had all the necessary ions and nutrients to 
allow the heart to contract outside the body. The stability of the heart was determined via 
measurements such as coronary flow rate, perfusion pressure, and temperature. A fluid-filled 
balloon inserted into the ventricle allowed measurement of contractile and relaxation 
parameters. Increasing doses of alpha-adrenergic receptor agonist, Methoxamine, were 
added to the KHB perfusate.  
I found that in response to alpha-adrenergic stimulation, there was a significant increase in 
the rate of contraction and the rate of relaxation in the healthy, wild-type mouse hearts, but 
not in the CaMKII knockout mouse hearts. There was a significant increase in the total 
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developed pressure in the heart during systole in the healthy mouse hearts in response to 
alpha-adrenergic stimulation, but this increase was not seen in the CaMKII knockout mice. 
There was also a significant reduction in the minimum pressure reached by the heart, and the 
end-diastolic pressure in the healthy wild-type mouse hearts in response to alpha-adrenergic 
stimulation. Again, this change was not seen in the CaMKII knockout mouse hearts.  
The results show that CaMKII may be responsible for the regulation of some contractile and 
relaxation parameters in the heart. By phosphorylation of its target protein, Ryanodine 
Receptor, CaMKII can increase the amount and rate of Ca2+ release into the cytoplasm of the 
cardiomyocyte which would allow for faster and more robust contractions. Furthermore, by 
phosphorylating Phospholamban, CaMKII can increase the rate and amount of Ca2+ cleared 
from the cytoplasm of the cardiomyocyte which would allow for faster and better relaxation. 
The results also tell us that CaMKII may be party of the alpha-adrenergic signaling pathway.  
Future research into the involvement of alpha-adrenergic signaling in cardiovascular 
pathology, and whether inhibiting CaMKII attenuates or completely ablates disease 
progression will allow us to target CaMKII or the alpha-adrenergic signaling pathway as a 
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1.1 Cardiovascular Disease in NZ 
Over the last decade, there have been many advances in medical research that have helped 
limit the epidemic of heart disease that is affecting many western societies. The development 
of statins and anti-hypertensive drugs have helped to reduce the morbidity of and mortality 
due to heart disease. However, despite such advances, cardiovascular disease remains to be 
one of the leading causes of death in New Zealand, with 33% of all deaths being caused by it 
(Ministry of Health, 2015). As of the 2015 NZ Health Survey, 186,000 kiwis are living with some 
form of cardiovascular disease (Ministry of Health, 2016).  
1.2 Basic Cardiac Function  
The function of the heart is to continually pump oxygenated blood into the aorta to be 
transported to other organs in the body so that they can carry out their functions effectively.  
1.2.1 Cardiac Anatomy  
There are four chambers that make up the heart- the right and left atria, and the right and 
left ventricles. The right atrium and ventricle receive deoxygenated blood from the body and 
pump to the pulmonary circulation so that oxygen from the lungs can oxygenate the blood. 
The left atrium and ventricle receive oxygenated blood from the pulmonary circulation and 
pump to the rest of the body. Each cycle of contraction and relaxation that the heart 
undergoes is known as the Cardiac Cycle. 
The heart muscle, known as the myocardium, is made up of individual, excitable cells known 
cardiomyocytes. Each cardiomyocyte is several contractile units that are made up of actin and 
myosin filaments. Cardiomyocytes also have an internal store of calcium (Ca2+) in the 
sarcoplasmic reticulum (SR) 
To undergo contraction, the cardiomyocytes have to depolarize. The heart has a small group 
of cells in the right atrium that are known as pacemaker cells that set the intrinsic heart rate. 
The pacemaker cells autonomously depolarize and the electrical potential spreads to 
neighboring cardiomyocytes via channels known as gap junctions. The rate at which the 
pacemaker cells depolarize is regulated by sympathetic and parasympathetic innervation that 
basally maintains the heart rate around 60-100 beats per minute in humans, and 500–724 
beats per minute in mice (Kaese and Verheule, 2012).  
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1.2.2 Cardiac Cycle  
1.2.2.1 Systole 
Systole is the phase of the cardiac cycle when the heart is contracting. Contraction in each 
cardiomyocyte occurs as a result of a process known as Excitation-Contraction Coupling, 
which begins when an electrical potential spreads to a cardiomyocyte. The depolarization 
triggers L-type Calcium Channels in the cell membrane to open. There is a subsequent small 
influx of Ca2+ ions into the cell. In close proximation to the cell membrane is the membrane 
of the SR. The influx of Ca2+ ions through L-type Calcium Channels triggers Ca2+-permeable 
channels, known as Ryanodine Receptor (RyR), in the SR membrane to change conformation 
and open. RyR opening causes efflux of a large concentration of Ca2+ from the intracellular 
Ca2+ store and into the cytoplasm of the cardiomyocyte, causing a dramatic increase in 
intracellular Ca2+. Myosin subunits are activated when the Ca2+ binds to them, however they 
have a low affinity for Ca2+ and thus, require a large concentration of Ca2+ in the cytoplasm to 
become functionally active. When the Ca2+ binds to myosin, the actin binding site is exposed 
and they bind to the actin filaments. Myosin also binds and hydrolyses Adenosine Tri-
Phosphate (ATP), and the energy released from this reaction causes the myosin to flex and 
pull the actin filaments closer to the center of the contractile apparatus. This results in the 
cardiomyocyte shortening and when several cardiomyocytes undergo this process 
simultaneously, contraction occurs (Bers 2002).   
1.2.2.2 Diastole 
Diastole is the phase of the cardiac cycle when the heart is relaxing. To relax, the Ca2+ in the 
cytoplasm must be removed and this is done in three ways. A small portion of the Ca2+ is 
removed by a secondary active transporter called the Sodium-Calcium Exchanger (NCX) that 
pumps Ca2+ out of the cell in exchange for sodium. Another way in which a small amount of 
the Ca2+ is removed is via the Calcium ATPase, which uses energy from ATP hydrolysis to pump 
Ca2+ out of the cell. The primary way in which Ca2+ is removed from the cytosol is by being 
pumped back into the intracellular Ca2+ store, the SR, by an ATP-dependent pump known as 
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Sarcoplasmic Endoplasmic Reticulum Calcium ATPase (SERCA). The basal activity of SERCA is 
downregulated by a protein known as Phospholamban (PLB). When the Ca2+ concentration in 
the cytoplasm decreases, myosin is no longer able to interact with actin and therefore the 
contractile filaments return to their basal length. This results in the cardiomyocyte relaxing 
and thus, so does the heart.  
1.2.3 Cardiac Output 
The cardiac output (CO; the volume of blood pumped out of the heart per minute; ml.min-1) 
can be altered by altering the heart rate (HR; the number of times the heart contracts per 
minute; beats.min-1) or the stroke volume (SV; the volume of blood that is pumped out per 
beat; ml.beat-1). In order to increase the CO, the body can increase either or both of the HR 
and the SV. An increase in HR and SV occurs in the presence of adrenaline/noradrenaline, 
which acts on adrenergic receptors (ARs) in the myocardium that cause an increase in the 
contractility, and rate of contraction and relaxation in the heart.   
1.2.3.1 Heart Rate  
Figure 1.1- Changes in 
the left ventricular 
pressure during the 
cardiac cycle. Two-
thirds of the cycle is 
spent in diastole, 
where the heart is 
relaxing and the 
ventricles are filling 
with blood.  One-third 
of the cycle is spent in 
systole, where the 
heart is contracting to 




The intrinsic rhythm of the heart beat is generated by pacemaker cells that generate an 
electrical potential that spreads to neighboring cells via gap junctions. The intrinsic rate at 
which these pacemaker cells generate electrical potentials can be altered by neuronal, 
endocrine or autocrine modulation. If the body requires the heart rate to be elevated, there 
is an increase in the sympathetic input and a decrease in the parasympathetic input to the 
pacemaker cells, and vice versa if the body required the heart rate to be decreased.  
1.2.3.2 Stroke Volume  
Changes in the stroke volume are caused by three factors- Preload, Afterload, and 
Contractility. The preload is defined by the amount of venous blood that returns to the heart 
from the systemic or pulmonary circulations. The higher the venous return, the higher the 
End-Diastolic Volume (EDV), which is the volume of blood in the ventricle at the end of 
diastole (Norton. 2001). Increased EDV increases the stroke volume by a mechanism known 
as length-dependent activation, whereby the increased blood volume causes the 
cardiomyocytes in the ventricular walls to stretch, in turn causing the contractile apparatus 
within these cardiomyocytes to also stretch. Because the actin and myosin filaments overlap 
each other, stretching of the cardiomyocytes reduces the overlap and allows more potential 
Figure 1.2- Length-Dependent Activation. A) When the cardiomyocyte is at basal length, 
there is more overlap between the actin and myosin filaments in the contractile apparatus. 
Only a few interactions between the actin and myosin are required to pull the actin 
filaments towards the midline, leading to a smaller contraction. B) When there is increased 
venous blood returned to the heart and the ventricles fill more, the cardiomyocytes are 
stretched, thus reducing the overlap between the actin and myosin filaments. The reduced 
overlap means that more interactions between the actin and myosin are required to pull 
the actin filaments towards the midline, leading to a greater contraction.  
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for the actin-myosin filaments to interact. More actin-myosin interaction causes a larger 
contractile force by shortening the contractile apparatus more and developing more tension 
as a result (See Figure 1.2). The afterload is defined by the pressure in the aorta that needs to 
be overcome by the ventricle to open the aortic valve and eject blood (Norton 2001). If there 
is a higher aortic pressure, the ventricular cardiomyocytes must develop more tension in 
order to increase the intraventricular pressure enough so that it is higher than that in the 
aorta. If the ventricle is not able to sustain the higher tension for the entirety of the systolic 
phase, the duration of the phase is shortened, and thus less blood is ejected which means 
there is a lower stroke volume. Over time, the heart can undergo modifications such as 
hypertrophy in order to compensate for the new need for higher tension development in the 
ventricular wall. 
1.3 Alpha1- Adrenergic Receptor 
1.3.1 Alpha-receptor Characterization  
There are 3 alpha receptor subtypes- alpha 1a/c, 1b, and 1d (Weinberg et al. 1994). Alpha 
adrenergic receptors are G-Protein Coupled Receptor (GPCRs) that mainly couple with Gaq 
proteins (Graham 1996). The protein structure is a single polypeptide chain made up of ~429 
- 561 amino acids, similar to other members of the same GPCR family. The receptors couple 
mainly with Gaq -proteins that consequently activates beta-isoform of Phospholipase C (PLC-
beta). PLC is an enzyme that cleaves Phosphotidylinositol-4, 5 Bisphosphate (PIP2) into 
Diacylglycerol (DAG) and 1, 4, 5-Inositol Triphosphate (IP3). IP3 is water soluble and can 
diffuse into the cytosol to the Sarcoplasmic Reticulum (SR) to activate ligand-gated Ca2+ 
channels and mediate Ca2+ release from SR stores into the cytosol. DAG is lipid soluble and 
thus stays close to the cell membrane, where it activates Protein Kinase C (PKC). 
Endogenously, they are activated by epinephrine and norepinephrine- catecholamines that 
are released in response to stress. Many agonists have been developed for alpha ARs. 
However, they lack specificity to any one subtype therefore making it difficult to determine 





1.3.2 Alpha1- AR Expression and Sensitivity in the Heart  
Ligand binding studies show humans have similar expression of alpha1ARs in the heart as 
mice and most other species. However, rats have a 10-fold higher expression comparatively 
(Jensen et al 2009, Noguchi et al 1995). Messenger Ribonucleic Acid (mRNA) for all three alpha 
AR subtypes have been found in the human heart (Jensen et al. 2009). Expression levels of 
alpha AR subtypes vary between species (Cotecchia 2010). In humans, the alpha1a/c subtype 
is the dominant subtype whereas in rodents, it is alpha-1b that is highly expressed in the 
heart.  While the alpha1d receptor subtype is expressed in very low levels in the myocardium 
itself, it is highly expressed in the coronary artery smooth muscle cells and activation causes 
vasoconstriction, which is when the lumen of the blood vessels reduces in diameter (Jensen 
et al. 2009). The alpha1b receptor subtype is also expressed in the endothelial cells of the 
coronary arteries and can cause vasodilation, which is when the lumen of blood vessels 
increases in diameter (Jensen et al. 2010).  
1.3.3 Localization and Signalling Pathways of Alpha1 ARs 
O'Connell et al (2014) review a novel view of GPCR signalling that occurs at the nuclear 
membrane and refer to it as "Inside Out" signalling. Alpha1ARs are thought to be primarily 
expressed on the plasma membrane because of ligand-binding studies (Fujita et al 2001). 
However, there is a lack of distinction between the membranes during the precipitation 
process which makes it hard to determine if the protein is on the plasma, sarcoplasmic or 
nuclear membrane. Studies have been done using a caveolar marker Caveolin-3, which is a 
vesicle that transports proteins from the SR to the plasma membrane and found roughly 20% 
of all alpha1ARs to be associated with caveolin-3 (Wright et al. 2008). When the nuclear 
membrane marker LAP2 is used, around 80% of all alpha1ARs were found to associate with it 
suggesting that a large proportion of alpha1ARs localize at the nuclear membrane (Wright et 
al. 2008).  
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Furthermore, lack of specific antibodies makes immunochemistry a less credible technique to 
determine alpha-AR localization as well. The Inside-Out theory is supported by the abundant 
presence of Organic cation transporter 3 (OCT3) in the heart which can transport 
catecholamines into the myocyte so that they can bind to the a1AR on the nuclear membrane. 
(Zwart 2001, Wright 2008). The well-known alpha antagonist prazosin is able to cross the 
plasma membrane freely as well.  
1.3.4 Effects of Activation in Normal Heart 
Addition of alpha-adrenergic agonist, Methoxamine, increased cytosolic free Ca2+ in isolated 
cardiomyocytes, due to efflux of Ca2+ from intracellular stores indicating it may have a positive 
effect on contractility of the heart (Eckel 1991). Alpha adrenergic stimulation evokes different 
responses in the right and left ventricles (Wang et al. 2006, Chu et al 2013). In the right 
ventricle, stimulation with a non-specific alpha agonist Phenylephrine caused a “triphasic 
response”, where there was an initial brief rise in developed force, followed by the large dip, 
and then a rise and plateau (Wang et al. 2006). However, this was overall a negative 
ionotropic response. In contrast, the left ventricle showed a positive ionotropic response, but 
in the same triphasic waveform, where the force initially peaked briefly, and dipped and rose 
again to a plateau. The dip in the force was not as deep in the left ventricle as it was in the 
Figure 1.3- Generic 
signalling pathway for Gaq 
Protein Coupled Receptor.  
When adrenalin/noradrenalin 
bind to the alpha adrenergic 
receptor,  
Protein Kinase C (PKC) and 
Calcium (Ca2+) act as second 
messengers for this 
pathway. PKC goes on to 
phosphorylate target 
proteins whereas can 
activate proteins and/or 
open channels to achieve 
the desired effect within the 
cell (González-Mariscal et al. 
2017).   
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right, and the rise to plateau was higher than the original baseline force, whereas in the right 
ventricle the plateau was lower than the baseline force. The literature conclude that the 
response is alpha1A specific because they saw a similar response to an alpha1A specific 
agonist A-61603. It is also proposed that the different subtypes represented in the heart have 
different effects- alpha1a AR subtype increases ionotropy (Ross et al., 2003; O-Uchi et al., 
2008). Transgenic Overexpression of the alpha1a subtype in mouse hearts has a positive 
effect on contraction , whereas that of the alpha1b subtype has a negative effect on 
contraction (Lin et al 2001; Grupp et al., 1998; Wang et al., 2000; Iaccarino et al., 2001; Lemire 
et al., 2001)  Transgenic knock-out of either of these subtypes has no effect on baseline 
cardiac function, suggesting that alpha1AR-mediated ionotropy is not needed in normal 
cardiac function (Rokosh and Simpson, 2002; Vecchione et al., 2002) 
1.3.5 Alpha1-AR and Cell Death  
In vitro studies involving cultured cardiac myocytes concluded that alpha1ARs are needed for 
cell survival signalling (Zhu et al., 2000). When these studies were translated in vivo, using 
transgenic mice that overexpress alpha1ARs or render them constitutively active, the results 
were variable (Du et al., 2004, 2006; Chaulet et al., 2006). On the contrary, studies that used 
transgenic mice that had loss-of function mutations in the alpha1ARs showed that these mice 
were worse off in conditions that simulated heart failure and ischemia, compared to the wild 
type counterparts, and they underwent pathological remodelling that largely involved 
cardiomyocyte cell death. They were able to come to the same conclusion as the in vitro 
studies, that alpha-1ARs are necessary for cellular survival. (O’Connell et al., 2006; Huang et 
al., 2007, 2008) 
1.4 Ca2+/Calmodulin-dependent protein Kinase II 
(CaMKII) 
Calcium/calmodulin-dependent protein Kinase II (CaM Kinase II or CaMKII) is a protein kinase 
that phosphorylates proteins, and is also able to autophosphorylate, and activate itself. It is 





1.4.1 Structure of CaMKII 
CaMKII is a dodecameric holoenzyme, which means that it is made up of 12 subunits that are 
arranged in two rings of 6 subunits. Each subunit is made up of four domains- one Ser/Thr-
specific kinase domain, one regulatory segment, a linker region that varies in length between 
different isoforms, and one hub/association domain. The hub domains of each subunit 
associate together to form the two rings of six subunits. In humans, there are four isoforms 
of CaMKII- α, β, γ, and δ. These vary mainly in the length of the linker region and in their 
expression levels in certain tissues. (Bayer et al 2002, Chao et al 2011) 
 
1.4.2 Localization of CaMKII 
The main CaMKII isoform in the heart is CaMKIIδ, of which there are two variants- δ3/B and 
δ2/C. CaMKIIδ3/B has an 11-amino acid sequence that localizes the CaMKII variant to the 
nucleus, while CaMKIIδ2/C lacks this nuclear localizing sequence and thus is localized in the 
cytosol. In vitro studies where both variants are expressed in cells in varying ratios also show 
that increased expression of the one variant influences the localization of the other variant. 
Furthermore, the CaMKIIδ2/C is more abundantly expressed variant in the adult heart. 
(Schworer et al 1993; Gray and Heller Brown 2014). 
1.4.3 Targets of CaMKII 
CaMKII plays a role in regulating Ca2+-handling proteins in the heart.  
 
 
Figure 1.4- 2-D structure of CaMKII 
Protein.  
Six subunits of CaMKII protein out of 
a total of twelve have been depicted 
in the image. Each subunit has three 
domains- Catalytic Domain (Yellow), 
Regulatory Domain (Blue) and 
Association Domain (Red) 
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1.4.3.1 Ryanodine Receptor (RyR) 
Ryanodine Receptor (RyR) is one of CaMKII's phosphorylation targets. The phosphorylation 
sites proposed are Serine-2809 and Serine-2815, both of which remain disputed by 
researchers who attribute the phosphorylation and resulting RyR regulation to Protein Kinase 
A (PKA). However, both sites are shown to be phosphorylated in heart failure when CaMKII 
has also been shown to have increased autophosphorylation, and diastolic Ca2+ leak from the 
SR in these rabbit heart failure models is reversed when CaMKII is inhibited, but not when 
PKA is inhibited, which supports the idea that CaMKII is a regulator of RyR (Maier et al 2007; 
Kohlhaas et al 2006). When CaMKII phosphorylates RyR, it increases the open probability of 
RyR by changing the conformation of the protein so that the pore size is greater and causes 
Ca2+ to leak out. 
1.4.3.2 Phospholamban (PLB) 
Another CaMKII target is Phospholamban (PLB), a protein that associates with the 
Sarcoplasmic/Endoplasmic Reticulum Calcium ATP-ase (SERCA) that pumps Ca2+ back into the 
SR during diastole to restore intracellular Ca2+ levels. PLB inhibits SERCA so that Ca2+ uptake 
into the SR is slower. However, when PLB is phosphorylated, its inhibitory effects on SERCA is 
reduced, and so Ca2+ uptake into the SR is faster. CaMKII phosphorylates PLB at Threonine-
17, but PLB can also be phosphorylated by PKA at Serine-16. If Ca2+ is pumped back into the 
SR faster, the heart is able to relax faster as well (Maier et al. 2007)  
1.4.4 Activation of CaMKII 
When CaMKII is inactivated, the regulatory domain is bound tightly to the catalytic/kinase 
domain of the enzyme on each of the subunits and therefore protein activity is auto-inhibited. 
An increase in intracellular Ca2+ causes Ca2+ binding to calmodulin to activate it, which in turn 
acts as a second messenger to activate various kinases, one of which is CaMKII. Ca2+/CaM bind 
to a site on the regulatory domain and cause a conformational change that exposes the 
catalytic/kinase domain. (Hudmon 2002)  
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1.4.5 Pathological Activation of CaMKII 
1.4.5.1 Oxidation 
CaMKII can also be activated by oxidation. In conditions where Reactive Oxygen Species (ROS) 
are elevated, such as inflammation or diabetes, CaMKII can be oxidised at Met 281 and 282 
which not only makes it autonomously activated, it also allows for autophosphorylation of 
the holoenzyme so that it is pathologically active. Furthermore, ROS also reduce phosphatase 
activity, which makes it harder to reverse CaMKII autophosphorylation, as well as reverse 
phosphorylation of its targets. (Erickson et al 2008; Mollova et al 2015).  
1.4.5.2 O-linked N-acetyl glucosamine 
Prolonged high blood glucose (hyperglycemia) can also cause post-translational modification 
of CaMKII and of other proteins, altering their function. A post-translational modification 
where O-linked N-acetylglucosamine is added to a protein (O-GlcNAcylation; O-GlcNAc) is 
seen in states where glucose is high, such as in a diabetes state. In high glucose states, there 
is a high concentration of a sugar called Uridine Di-Phosphate-N-acetylglucosamine that is the 
substrate of O-GlcNAc. The addition of this sugar to proteins is catalysed by an enzyme called 
O-GlcNAc Transferase, and the removal is facilitated by O-GlcNAcase. CaMKII can undergo 
this modification on Threonine-286 and Serine-279. CaMKII has been shown to have 
increased activity in high glucose conditions, and the increased activity is abolished when an 
O-GlcNAc modification inhibitor, Diazo-5-Oxonorleucine, was added. When an O-GlcNAcase 
Figure 1.5- 2-dimensional 
depiction of the activation 
of CaMKII protein.  
The image shows a calcium-
bound calmodulin molecule 
binding to and acting on the 
regulatory domain of 
CaMKII.  
The activation domain 
undergoes a subsequent 
conformational change and 




inhibitor is added, CaMKII activity is increased, which provides strong evidence for the 
pathological activation of CaMKII in diabetes (Erickson et al 2013).  
1.4.6 Autonomous Activity of CaMKII 
The kinase domain can go on to phosphorylate and activate CaMKII's targets, or it can 
autophosphorylate on the Threonine-286/7 amino acid, which reduces the binding affinity of 
the regulatory domain for the catalytic/kinase domain. In other words, phosphorylation at 
the Threonine-286/7 site releases CaMKII autoinhibition, and thus the enzyme can remain 
active even when the intracellular Ca2+ concentrations are decreased, and Ca2+/calmodulin is 
no longer bound to CaMKII (Hudmon 2002). Mutations introduced to substitute Threonine-
286/7 with amino acids that cannot be phosphorylated showed that the CaMKII enzyme was 
still functional in the presence of Ca2+/CaM but could not function autonomously. Therefore, 
this phosphorylation site is needed for CaMKII to function independently of Ca2+/CaM 
(Hudmon 2002). The main benefit of autophosphorylation is to allow for potentiation of the 
signal when Ca2+ spikes occur in high frequencies. For example, when heart rate is high, 
depolarization occurs at a high frequency and the period between each spike of Ca2+ is short 
enough so that there isn't enough time for the activated CaMKII subunit to dephosphorylate 
and become inactive before the next spike occurs. Another subunit may become activated, 
and subsequently autophosphorylated by the first subunit. The significance of the varying 
length of the linker region between the different CaMKII isoforms is that if the linker region is 
short in length, the enzyme spends more time in a compact configuration that makes its 
Ca2+/CaM binding site harder to access. A compact configuration means that the CaMKII 
needs a higher frequency of Ca2+ spikes to trigger autophosphorylation and activation of the 
enzyme. With a long linker region, the enzyme spends more time in an extended configuration 
that makes its Ca2+/CaM binding site easier to access, so it is more likely to autophosphorylate 
and become activated, even at a lower frequency of Ca2+ spike 
Furthermore, autophosphorylation has been shown to increase the affinity for Ca2+/CaM by 
over 1000x (Hudmon 2002). This phenomenon has been referred to as CaM trapping. This 
sequence of Ca2+/CaM binding, autophosphorylation, and CaM trapping gives CaMKII the 
ability to be sensitive to Ca2+ spike frequencies, which means that at higher frequencies it is 
able to tailor its enzyme activity to the frequency of spikes that occur (Hudmon 2002). This 
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can be beneficial in a healthy heart by allowing for potentiation of the Ca2+ signalling and thus, 
a stronger response.  
1.4.7 Effects on Gene Expression 
Overexpression of the CaMKIIδ3/B subtype develop hypertrophy but did not show an increase 
in phosphorylation of CaMKII's targets. It is thought that the nuclear localization of this 
subtype along with the lack of increased phosphorylation in the transgenic models imply that 
this subtype is more involved in gene expression, namely hypertrophic genes. (Zhang 2007; 
Gray and Heller Brown 2014).CaMKIIδ3/B is thought to promote cell survival through gene 
expression by upregulating expression of anti-apoptotic factors Bcl2 and inducible Heat Shock 
Protein 70 in stressful conditions (Little et al 2009; Peng et al 2010; Gray and Heller Brown 
2014). The CaMKIIδ2/C variant has also been shown to activate the transcription factor HDAC4 
(Zhang et al 2007). As opposed to CAMKIIδ3/B, CaMKIIδ2/C is thought to promote cell death 
through gene expression, such as by upregulating p53 and NF-kB, both of which are pro-
apoptotic transcription factors (Toko et al 2010; Ling et al 2013; Gray and Heller Brown 2014).  
1.5 Aim and Hypothesis  
The aim of this project was the determine the functional effects of the alpha-adrenergic 
agonist Methoxamine on isolated wild-type mouse hearts, and in isolated CaMKII knockout 
mouse heart, in incremental doses to observe differences in the responses between the two 
groups to determine the role of CaMKII in the functional response to alpha-adrenergic 
stimulus in the heart.  
I hypothesize that in response to methoxamine, the contractility of the mouse hearts will 
increase because of the increased cytosolic Ca2+. However, I hypothesize that the CaMKII 
knockout mouse hearts will show a diminished responsiveness to alpha stimulation and thus 
have a smaller increase in contractility compared to the wild-type mouse hearts because of 
the role that CaMKII plays in upregulating Ca2+-handling proteins in the heart and because of 
















2.1 Ethics  
Ethical Approval for this project was provided by the University of Otago Animal Ethics 
Committee under the ethics code ET09/15. The experiments were compliant with the 
committees Code of Ethical Conduct, and with the Animal Welfare Act 1999. Any genetically 
modified animals imported were approved by Environmental Protection Agency (EPA; 
formerly ERMA) and by the Institutional Biological Safety Committee (IBSC).   
2.2 Animals 
2.2.1 Animal Model  
C57Bl/6 Mice species variant were used as wild-type mice, and a genetically modified strain 
of the C57Bl/6 mouse species where the CaMKII protein is knocked out were also used. These 
mice were house in the Hercus Taieri Research Unit (HTRU) in groups of up to four mice with 
ad libitum access to standard chow and water.  
2.2.2 Groups 
There were two groups in the experiment. The first group was the Control group, made up 
exclusively of Wild Type C57Bl6 mice (WT). The second group was the genetically modified 
group, made up exclusively of the CaMKII Knock Out mice (KO). There were 6 mice in each 
group.  
2.3 Echocardiography  
The mice were first anaesthetized with 3% Isoflurane in a gas chamber. Once the fur from the 
thorax was removed, a parasternal short-axis echocardiograph was performed (GE Vivid 
E9/EchoPAC PC system) to attain measurements for in-vivo heart function parameters.  
2.3.1 In-Vivo Heart Function Parameters  
2.3.1.1 LV Fractional shortening (FS; %)  
Fractional shortening is a measure of how much the internal diameter of the left ventricle is 
reduced by when the heart contracts during systole, compared to when it is relaxed during 







Where- FS = Fractional Shortening (%) 
LVIDd = Left Ventricle Internal Diameter in diastole (cm) 
LVIDs = Left Ventricle Internal Diameter in systole (cm) 
 
2.3.1.2 Ejection Fraction (EF; %)  
Ejection Fraction is a measure of how much of the volume of blood in the left ventricle at the 
end of diastole is pumped out of the ventricle when the heart contracts during systole. This 
gives us a way to measure how effectively the heart is contracting. It can be defined by the 










Where- EF = Ejection Fraction %) 
SV = Stroke Volume (mL)  
EDV = End Diastolic Volume (mL)  
ESV = End Systolic Volume (mL) 
 
2.3.1.3 Cardiac Output (CO; l/min) 
Cardiac Output is a measure of the volume of blood that is pumped out of the left ventricle 
per minute. It can be defined by the following equation (Chengode, 2016)-  
𝐶𝑂 (𝑚𝐿. 𝑚𝑖𝑛−1) = 𝑆𝑉 × 𝐻𝑅 
Where- CO = Cardiac Output (mL.min-1) 
SV = Stroke Volume (mL.beat-1)  






2.4 Heart Extraction  
2.4.1 Pre-surgical Procedures  
Prior to surgery, the mice were injected with 0.1 ml 10Units of Heparin in 0.9% Saline 
intraperitoneally. Heparin is an anticoagulant which minimises the coagulation of blood in the 
coronary arteries to allow better perfusion of the heart during the Langendorff. The tibia 
length was measured with digital callipers and blood glucose was measured from the tail tip 
using an AccuCheck glucometer after the heparin injection was given. The body weight was 
also recorded prior to anaesthesia.  
2.4.2 Surgery to excise the heart 
The mice were overdosed with 5% Isoflurane inhaled through a nose cone and their pedal 
withdrawal-reflex was checked to ensure successful anesthesia. The overlying skin on the 
thorax was removed, and a transverse incision was made just below the xiphoid process, 
inferior to the diaphragm. The diaphragm was then cut to gain access to the thoracic cavity. 
A timer was started to record the amount of time taken to cannulate the heart from when 
the diaphragm was cut. Two longitudinal incisions were made through the rib cage at the mid-
clavicular line. The sternum and attached ribs were then reflected upwards to expose the 
heart. Fine surgical forceps and scissors were used to clamp the aorta at the arch and the 
aorta was cut. The heart was then removed with a small portion of the aorta exiting the heart 
still intact.  
2.4.3 Arresting Solution  
The heart was immediately placed in a warm, high potassium Krebs Henseleit Buffer solution. 
The high potassium concentration in the arresting solution would cause the heart to arrest by 
saturating the electrical gradient, and the other salts and glucose would allow the cells to 
continue being metabolically active and prevent cell death so that they can restore their 






Table 2.1- Composition of Krebs Henseleit Buffer used in arresting solution 
Components Molecular Weight (kDa) Concentration (mmol.L-1) 
KCl 74.6 18.8 
NaCl 58.4 118.5 
MgO4S.7H2O 246.5 1.2 
KH2PO4.H2O 136.1 1.2 
NaHCO3 84 25.0 
Glucose 198.2 11.0 
CaCl 147 1.5 
 
2.5 Langendorff Setup 
The Langendorff setup was first developed by Oscar Langendorff in 1895 as a means to 
perfuse an isolated mammalian heart in a retrograde fashion (Bell 2011). Figure 2.1 shows a 
schematic representation of the Langendorff setup.  
2.5.1 Perfusion Buffer 
In order to keep the heart beating, the cardiac tissue must be supplied with a number of 
electrolytes, glucose, pH regulation, thermoregulation, and oxygen. The buffer used in these 
experiments was Krebs Henseleit Buffer (KHB) with the following composition-  
Table 2.2- Composition of Krebs Henseleit Buffer used in perfusing solution 
Components Molecular Weight (kDa) Concentration (mmol.L-1) 
KCl 74.6 4.7 
NaCl 58.4 118.5 
MgO4S.7H2O 246.5 1.2 
KH2PO4.H2O 136.1 1.2 
NaHCO3 84 25.0 
Glucose 198.2 11.0 
CaCl 147 1.5 
 
The buffer had a pH of 7.4 and was maintained at a temperature of 36.5°C-37.5°C by a water 
bath (Julabo GMBH, Seelbach, Germany). Carbogen (95% O2 and 5% CO2) was bubbled 



















































































































































































































































































































































































































































































































































































The buffer was pumped through a series of tubes with the help of a peristaltic pump 
(ADInstruments, NZ). The perfusion pressure was kept constant at 75 mmHg, and flow was 
adjusted accordingly to maintain that perfusion pressure. The buffer was also passed through 
a 0.45 µM filter (Simplepure™ PES Syringe Filter, Membrane Solutions, WA, USA). A 10 mL 
syringe filled partly with air and partly with buffer was also incorporated into the set up, and 
acted as a Windkessel which helped reduce the pulsatility of flow in the same way that the 
complaint walls of the aorta would in-vivo. This allowed the coronary flow remained 
consistent during both systole and diastole so that there was consistent perfusion to the 
coronary arteries.  
2.5.2 Basal Parameters  
Two pressure transducers (Physiological Pressure Transducer, ADInstruments, NZ) allowed 
measurement of coronary pressure and left ventricular pressure. Information from both the 
pressure transducers was relayed to PowerLab and subsequently, the information was 
converted to digital data that is interpreted by the LabChart software.   
The coronary pressure was detected by a fluid filled tube that inserted into the main perfusion 
system, close to the cannula that the aorta would be tied onto. Fluid in the tube was displaced 
when there was a change in the coronary pressure.  The fluid displacement that was detected 
by the pressure transducer which allowed for the most direct reading of the coronary 
pressure.  
The left ventricular pressure was detected by a fluid-filled balloon that was inserted into the 
left ventricle via the left atrioventricular valve upon removal of the left atrium. The balloon is 
empty when inserted, but gradually filled with distilled water to inflate it. 10-15 µL of distilled 
water was injected into the balloon, depending on the size of the balloon. When heart 
contracted, the balloon was squeezed, and displacement of the fluid was detected by the 
pressure transducer.   
Coronary flow was measured by a flowmeter and transmitted via PowerLab to the LabChart 
software. A temperature probe was placed in a water bath that the cannulated heart was 
submerged in to ensure the heart was constantly at optimal temperature between 36.5°C and 




2.5.3. Cannulation  
A 23-gauge needle was modified to have a flat tip, with circular grooves indented close to the 
tip was used as the cannula, as this was the correct diameter to fit a mouse aorta and the 
grooves allowed for the aorta to be tied on with surgical silk without sliding off the cannula. 
The heart was removed from the arresting solution and placed in a petri-dish with arresting 
buffer in it. The tip of the cannula was also submerged in the arresting buffer in the petri dish 
so as to minimize bubbles being introduced during cannulation. Surgical forceps were used 
hold the cut end of the aorta and slide it onto the cannula. Once the aorta was cannulated, it 
was held on the cannula with a bulldog clamp briefly before surgical silk was used to tie it on.  
Once the heart was tied onto the cannula, the cannula was secured on a clamp that hung the 
heart into a small, double-jacketed glass water bath that had water at 37°C circulating within 
it, and warm, oxygenated buffer that the heart sat in. This allowed further regulation of the 
temperature immediately around the heart.  
The coronary flow was then slowly increased until the coronary pressure was 75 mmHg, at 
which point the pressure was held constant. The heart was allowed to stabilize at this new 
pressure and flow for three minutes. The left atrium was removed and the empty pressure 
sensing balloon was inserted into the left ventricle, via the left atrioventricular valve. The tube 
attached to the balloon was taped to the cannula so that the balloon stayed in place. The 
balloon was filled with distilled water at 2 µL at a time, with at least one minute of stabilization 
time in between each fill. When the max volume was reached (~ 10 – 15 µL), the heart was 
allowed another stabilization period of five minutes.  
2.5.4 Ex-Vivo Heart Function Parameters  
LabChart software allowed for measurement and calculation of several parameters. These 
can either be used to determine the performance of the heart during systole (Systolic 
Function) or during diastole (Diastolic Function).  
2.5.4.1 Systolic Function  
Max Pressure is the maximum pressure developed during one ventricular cycle.  
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Systolic Duration is the time the ventricles spend contracting. It is calculated as the time 
between the End-Diastolic Pressure and the start of the Min dP/dT measurement on the 
ventricular cycle.  
Max dP/dT is a measure of how fast the heart is able to contract, that is, the change in the 
pressure over time. LabChart calculates this as the steepest slope during the upstroke of one 
ventricular cycle.  
 
Developed Pressure is how much pressure the ventricles are able to develop during 
contraction, calculated as the difference between the maximum pressure and the minimum 
pressure in one ventricular cycle.  
2.5.4.2 Diastolic Function  
Min Pressure is the minimum pressure reached when the ventricles relax during one 
ventricular cycle.  
Diastolic Duration is the time the ventricles spend relaxing. It is calculated as the time 
between the start of the Min dP/dT measurement and the end of the ventricular cycle.  
Min dP/dT is a measure of how fast the heart is able to relax. LabChart calculates this as the 
steepest slope during the down stroke of one ventricular cycle.  
End-Diastolic Pressure (EDP) is pressure in the ventricle at the end of diastole when the heart 
has fully relaxed, and before the start of systole where the heart begins to contract. It is not 
Figure 2.2- LabChart Analysis View of one ventricular pressure waveform. The measured 
parameters of End-Diastolic Pressure (EDP), Rate of Contraction (Max dP/dT), Maximum 
Pressure (Max Pressure), Rate of Relaxation (Min dP/dT), and Minimum Pressure (Min 
Pressure)  are marked on the waveform.  
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the lowest pressure in the cycle (which is the Min Pressure), because at the end of diastole 
the ventricles have filled with blood which raises the ventricular pressure slightly, even 
though the ventricles have not started contracting yet. LabChart calculates this geometrically 
to keep the EDP point consistent between all the waveforms.   
2.5.4.3 Other Measures  
Heart Rate is the number of times the ventricles contract in 60 seconds. LabChart calculates 
the heart rate as 60 divided by the duration of one ventricular cycle. 
2.6 Experimental Protocol   
2.6.1 Baseline Ex-Vivo Function  
The heart was allowed to stabilize for 2 minutes after the balloon was inserted and filled. This 
was followed by a 3 minute baseline recording.  
2.6.2 Methoxamine (MTX) Dose Curve  
Once the heart was stabilized, a MTX dose curve was performed. Three doses were used; 10-
8, 10-6, and 10-4. The doses used were determined based on doses used in the literature. 
Schumann et al. (1975) used the 10-4 dose of MTX on rabbit papillary muscles and showed an 
increase in developed tension. It took approximately three minutes for a 10-4 dose of MTX to 
cause a significant increase in the developed tension in the rabbit papillary muscle, which was 
shown to be a slower effect compared to beta-adrenergic agonists (Schumann et al. 1975) 
To perfuse the heart with MTX at 10-8, 250 μL of a 10 µM stock solution was added to 250 mL 
of KHB solution that had already been warmed in the water bath and carbogenated. The 
solution was perfused through the setup and to the heart for 15 minutes, which allowed 
sufficient time for the solution to flow through the setup itself and reach the heart, as well as 
for the MTX to act on the alpha-adrenergic receptors in the heart tissue. 
Similarly, when treating with MTX at 10-6, 2.5 mL of a 100 µM stock solution was added to 
250mL of the warmed, carbogenated KHB solution and perfused for 15 minutes, and when 
treating with MTX at 10-4, 2.5 mL of a 10 µM stock solution was added to 250 mL of the 
warmed, carbogenated KHB solution and perfused for 15 minutes.  
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Between doses, there were no washout periods. Therefore, the doses were additive. 
However, the purpose of the dose curve was to elicit an incremental response to increasing 
doses of the drug, and the doses were increased 10-fold each time, making them an 
inconsequential addition to the next dose up. Thus a washout was not deemed necessary.  
2.6.3 Tissue storage  
At the end of the final dose perfusion period, without any washout period, the heart was 
removed from the cannula. The left ventricle, right atrium, and right ventricle were dissected 
and snap-frozen immediately in liquid nitrogen. This was done so that the MTX treated tissue 
could be used for future investigations into the acute effects of alpha stimulation on protein 
modifications in cardiac tissue. However, this was not looked at in this thesis.  
2.7 Data Analysis  
2.7.1 Echocardiography Data Analysis  
Echocardiographs were analyzed on the GE Vivid E9/EchoPAC PC system to acquire raw values 
for in-vivo parameters (See Section 2.3.1). Five measurements were taken of the posterior 
wall and interventricular septum, in both diastole and systole. From this, the internal 
diameter of the left ventricle could be calculated for each of diastole and systole. Three 
measurements were taken from diastole of one cycle to diastole of the consecutive cycle, 
which allowed calculation of the heart rate. Figure 2.3 shows a cross sectional schematic of 
the heart from the echocardiograph. Figure 2.4 shows the points on the echocardiography 
trace where each of the in-vivo measurements were taken.  
2.7.2 Langendorff Data Analysis   
Data analysis was performed using LabChart Pro 7 to collect data points, Microsoft Excel 2016 
to collate the data, and GraphPad Prism 7 to perform statistical analyses.  
Data points were derived from the last 3 minutes of the 15 minute perfusion period set for 
each dose. LabChart produced the values for every parameter for every contraction within 
the selected region on the trace. The points were copied from the data pad to Microsoft Excel. 
The raw data averages were compiled on Microsoft Excel to calculate the change from 
baseline and fold change.  
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The raw data averages, change from baseline, and the fold change for each parameter were 
analyzed on GraphPad using a 2-way ANOVA to determine if there were differences between 
the WT and KO groups for each dose, as well as if there were changes between the increasing 
doses of MTX within each group. Significance was drawn at p<0.05.  
  
 
Figure 2.3- 2-dimension cross-sectional image of the 
mouse heart as seen on the echocardiograph.  
Labelled on the image is the right atrium (RA; blue 
shading), the left ventricle lumen (LV Lumen; grey 
shading), and the myocardial wall (red shading) with 
the interventricular septum (IVS) and the left 
ventricular posterior wall (LVPW) 
Figure 2.4- Example echocardiography trace from which in-vivo echo parameters were 
measured.   
The following measurements were taken from the echocardiography trace- Thickness of the 
interventricular septum diameter during diastole (IVSDd) and during systole (IVSDs), thickness of 
the left ventricular posterior wall during diastole (LVPWd) and during systole (LVPWs), left ventricle 
internal diameter during diastole (LVIDd) and during systole (LVIDs), and heart rate (HR). The white 













3.1 Basal parameters  
There were 6 mice in each of the WT and KO groups. Average values, standard errors of mean, 
and p values have been presented in Table 3.1. Basal parameters of age, blood glucose, 
weight, and tibia length were measured for all mice used in the experiments. There was no 
difference in the age between the WT and KO groups or in the tibia length between the WT 
and KO groups. While there was no statistical difference in the blood glucose between the 
WT and KO mice, there appears to be a trend towards the KO mice having a lower blood 
glucose compared to the WT mice. The mice in the KO group had a greater weight on average 





WT (n=6) KO (n=6) 
Age (days) 106.3 ± 7.233 114.8 ± 5.873 0.3831 
Body Weight (g) 40.17g ± 2.203 31.2 ± 0.4066 0.0025** 
Blood Glucose (mmol/L) 12.08 ± 1.169 9.45 ± 0.3233 0.0550 
Tibia Length (mm) 15.84 ± 0.4292 16.02 ± 0.4187 0.7640 
3.2 In-vivo echocardiography parameters  
The average values, standard errors of mean, and p values have been presented in Table 3.2. 
In-vivo parameters of FS, EF, CO, SV, HR, LVIDs and LVIDd were measured for mice from both 
groups. There was no difference between the mice in the WT and KO groups for any of the 
parameters measured during the echo.   
 
WT = Wild Type Group; KO = Knock Out Group; all values displayed as mean ±SEM. 
Unpaired t-test used to compare groups for all parameters. * = p<0.05; ** = p<0.01.  




3.3 Baseline parameters  
During the baseline protocol, there was not difference between the WT and KO groups in any 
of the systolic parameters. The WT and KO groups showed no statistical difference in the max 
pressure (WT= 44.37 ± 7.124; KO= 35.02 ± 11.77; p= 0.5120), systolic duration (WT= 0.08522 
± 0.01302; KO= 0.1026 ± 0.01302; p= 0.3683), max dP/dT (WT= 1383 ± 222.4; KO= 994 ± 280.4; 
p= 0.3025), and developed pressure (WT= 37.54 ± 6.245; KO= 28.82 ± 10.95; p= 0.5045).  
The diastolic parameters also showed no difference during the baseline protocol between the 
two groups. The WT and KO groups showed no statistical difference in the min pressure (WT= 
6.83 ± 1.201; KO= 6.201 ± 1.056; p= 0.7025), EDP (WT= 8.132 ± 1.325; KO= 7.378 ± 1.152; p= 




WT (n=3) KO (n=4) 
FS (%) 41.48 ± 4.563 40.2 ± 3.125 0.8203 
EF (%) 78.12 ± 4.651 76.96 ± 3.362 0.8424 
SV (L) 0.08793 ± 0.00448 0.08337 ± 0.007655 0.6610 
CO (L/min) 0.03673 ± 0.00444 0.0367 ± 0.003606 0.9959 
HR (beats/min) 416.2 ± 40.35 443.2 ± 37.02 0.6455 
LVIDd (mm) 2.072 ± 0.1688  2.096 ± 0.1832 0.9290 
LVIDs (mm) 3.539 ± 0.01909 3.489 ± 0.1465 0.7839 
Table 3.2- Table showing the in-vivo echocardiography parameters of the 
WT and KO mice.  
WT = Wild Type Group; KO = Knock Out Group; all values displayed as mean ±SEM. 
Unpaired t-test used to compare groups for all parameters. * = p<0.05; ** = p<0.01.  
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dP/dT (WT= -701.9 ± 90.8; KO= -556.4 ± 99.16; p= 0.3047). Heart rate also showed no 









3.4 Ex-vivo heart function parameters 
3.4.1 Systolic function  
3.4.1.1 Maximum pressure  
There was no statistically significant increase in the max pressure with increasing doses of 
methoxamine in both, the WT and the KO groups. In the WT group, compared to baseline, 
there is no significant change in the max pressure in response to MTX doses 10-8 (p= 0.9937), 
10-6 (p= 0.9572), 10-4 (p= 0.2704). In the KO group, compared to baseline, there is no 
Figure 3.1- Graphs showing baseline comparisons of systolic function parameters. A) Max 
Pressure B) Systolic Duration C) Max dP/dT D) Max-Min Pressure. WT = Wild Type Group; KO = 
Knock Out Group; all values displayed as mean ±SEM. Unpaired t-test used to compare groups 
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significant change in the max pressure in response to MTX doses 10-8 (p= 0.9987), 10-6 (p= 
0.9991) and 10-4 (p >0.9999). There was also no difference between the WT and KO groups at 
the MTX 10-8 dose (0.9669 vs. 1.019; p= 0.9969), MTX 10-6 dose (0.9355 vs. 0.9826; p= 0.9980), 
and the MTX 10-4 dose (1.236 vs. 1.006; p= 0.5766).  
3.4.1.2 Systolic Duration  
In the WT group, there was no statistically significant change in the systolic duration in 
response to MTX 10-8 (p= 0.8621), MTX 10-6 (p= 0.5929), and MTX 10-4 (p= 0.9939). In the KO 
group, there was no statistically significant increase in the systolic duration in response to 
MTX 10-8 (p= 0.9900), MTX 10-6 (p= 0.9976), and MTX 10-4 (p= 0.9426). There was also no 
difference between the WT and KO groups at the MTX 10-8 dose (0.9315 vs. 1.027; p= 0.7694), 
MTX 10-6 dose (0.8894 vs. 0.9835; p= 0.7768), and MTX 10-4 dose (1.023 vs. 1.049; p= 0.9974).  
 
Figure 3.2- Graphs showing baseline comparisons of diastolic function parameters. A) Min Pressure 
B) EDP C) Diastolic Duration D) Min dP/dT. WT = Wild Type Group; KO = Knock Out Group; all values 
displayed as mean ±SEM. Unpaired t-test used to compare groups for all parameters. * = p<0.05; ** = 
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3.4.1.3 Max dP/dT  
There was a statistically significant increase in the max dP/dT in the WT group at the MTX 10-
4 dose where there is an average 1.384-fold increase (p= 0.0114), which means the rate of 
contraction increased in response to the highest methoxamine dose in the WT mice. 
However, there was no significant change in the max dP/dT at the MTX 10-8 (p= 0.9103) and 
10-6 doses (p= 0.8094). The KO group showed no change in the max dP/dT at the MTX 10-8 (p= 
0.3105), MTX 10-6 (p= 0.2583), and MTX 10-4 (p= 0.5080) dose. There was also no statistically 
significant difference between the WT and KO groups at the MTX 10-8 dose (1.079 vs. 1.21; p= 
0.9065), MTX 10-6 dose (1.106 vs. 1.224; p= 0.9348), and MTX 10-4 (1.398 vs. 1.167; p= 0.5561).  
3.4.1.4 Developed Pressure  
There was a statistically significant 1.407-fold increase in the developed pressure in the WT 
group in response to the MTX 10-4 dose (p= 0.0206), but not in response to the MTX 10-8 dose 
(p= 0.9908) or the MTX 10-6 dose (p= 0.9921). There was no significant increase in the 
developed pressure in the KO group in response to the MTX 10-8 dose (p= 0.8631), the MTX 
10-6 dose (p= 0.9435), or the MTX 10-4 dose (p= 0.8750). There is also no statistically significant 
difference between the WT and KO groups at the MTX 10-8 dose (1.039 vs. 1.102; p= 0.9941), 
MTX 10-6 dose (1.037 vs. 1.073; p= 0.9993), or MTX 10-4 dose (1.407 vs. 1.099; p= 0.3174).  
3.4.2 Diastolic Function  
3.4.2.1 Min Pressure  
The mice in the WT group showed a statistically significant decrease in min pressure with 
increasing methoxamine dose. At the MTX 10-8 dose, the min pressure decreases to 0.5418 of 
the baseline min pressure (p= 0.0299), at the MTX 10-6 dose, it decreases further to 0.3412 of 
the baseline value (p= 0.0011), and at the MTX 10-4 dose, it decreases more so to 0.2523 of 
the baseline value (p= 0.0002). However, in the KO group there is no significant decrease in 
the min pressure at any of the doses of methoxamine. At MTX 10-8, the min pressure in the 
KO mice is 0.7438 of baseline (p= 0.3690), at MTX 10-6, it is 0.6928 of baseline (p= 0.2204), 
and at MTX 10-4 it is 0.7811 of baseline (p= 0.5051). There is no difference in the change in 
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Figure 3.3- Graphs showing fold change in systolic function parameters in WT and KO mice in 
response to increasing MTX doses A) Max Pressure B) Developed Pressure C) Max dP/dT D) Systolic 
Duration. WT = Wild Type Group; KO = Knock Out Group; MTX= Methoxamine all values displayed as 
mean fold change from baseline ±SEM. Two-way Anova used to compare changes between WT and 
KO groups, and to compare changes between doses within each group. * = p<0.05 for WT group only 
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3.4.2.2 End Diastolic Pressure  
The EDP showed a similar trend to the Min Pressure in that there was a significant reduction 
in the EDP in the WT group at the MTX 10-6 dose (0.4689-fold change; p= 0.0021) and MTX 
10-4 dose (0.4237-fold change; p= 0.0008) compared to the baseline. However, there was no 
significant change at the MTX 10-8 dose (0.7634-fold change; p=0.0522). However, in the KO 
group, there was no significant change in the EDP at the MTX 10-8 dose (0.7634-fold change; 
Figure 3.4- Graphs showing fold change in diastolic function parameters in WT and KO mice in 
response to increasing MTX doses A) Min Pressure B) End-Diastolic Pressure C) Min dP/dT D) Diastolic 
Duration. WT = Wild Type Group; KO = Knock Out Group; MTX= Methoxamine all values displayed as 
mean fold change from baseline ±SEM. Two-way Anova used to compare changes between WT and 
KO groups, and to compare changes between doses within each group. * = p<0.05 for WT group only 




p=0.3030), MTX 10-6 dose (0.7423-fold change; p=0.1877), or the MTX 10-4 dose (0.786-fold 
change; p=0.3891). There was also no significant difference between the WT and KO groups 
at any of the three doses.  
3.4.2.3 Min dP/dT 
The min dP/dT showed a significant fold change of 1.435 at the MTX 10-4 dose in the WT group 
(p= 0.0066), which means the rate of relaxation was faster in the WT mice at the highest 
methoxamine dose. However, there was no significant change at the MTX 10-8 (1.115-fold 
change; p=0.7826) and MTX 10-6 (1.162-fold change; p= 0.5573) in the WT group. In the KO 
group, there was no significant change in the min dP/dT at the MTX 10-8 dose (1.206-fold 
change; p= 0.3483), MTX 10-6 dose (1.252-fold change; p=0.1909), or the MTX 10-4 dose 
(1.156-fold change; p= 0.5862). There was also no significant difference between the WT and 
KO groups at any of the three doses.  
3.4.2.4 Diastolic Duration  
In the WT group, there was no statistically significant change in the diastolic duration at the 
MTX 10-8 dose (1.007-fold change; p> 0.9999), or the MTX 10-6 dose (0.9611-fold change; 
p=0.9144), or at the MTX 10-4 dose (1.112-fold change; p= 0.8889). In the KO group, there was 
no statistically significant change in the diastolic duration at the MTX 10-8 dose (1.175-fold 
change; p=0.6751), or the MTX 10-6 dose (1.331-fold change; p= 0.1658), or at the MTX 10-4 
dose (1.162-fold change; p=0.7250). There was also no statistical difference between the WT 





















This thesis is concerned with the role of alpha-adrenergic receptor activity and the role of 
CaMKII in the heart. My project used an isolated heart perfusion system, where the alpha1-
AR agonist, methoxamine, was used to address the first aim of this project- to determine the 
response of alpha-AR stimulation in the isolated heart of WT mice. The second aim of this 
project was to determine if CaMKII is involved in mediating the response to alpha-AR 
stimulation in the isolated heart, and CaMKII knockout mice were used. 
I had hypothesized that there would be a positive contractile response, that is, increased max 
pressure, increased max dP/dT, and increased developed pressure in the WT mouse hearts 
when the alpha-AR agonist is applied. I also hypothesized that there would be a faster cardiac 
cycle, that is a shorter systolic and diastolic duration, and thus an increased in the heart rate 
in the WT mouse hearts. With respect to CaMKII involvement, I had hypothesized that CaMKII 
is involved in the mediating the effects of alpha-AR signalling in the heart, and thus the 
functional changes seen in the WT hearts in response to alpha-AR stimulation would be lost 
in the KO mouse hearts when methoxamine was added.  
4.1 Does alpha-AR stimulation have functional effects 
in the isolated heart and is CaMKII involved in 
producing these effects? 
4.1.1 Systolic Function   
The WT mouse hearts were responsive to the highest dose of MTX, as seen in the increase in 
Max dP/dT and Pdev.  
The rate of contraction increased in the isolated WT mouse hearts when 10-4 MTX was added 
to the perfusate. With this, we can conclude that alpha-AR stimulation increases the rate of 
contraction in the normal heart. However, this increase is not seen in the KO mouse hearts. 
This implicates CaMKII as a mediator for the increased rate of contraction in response to 
alpha-AR stimulation. This can be explained through the downstream proteins activated by 
CaMKII- namely, RyR and PLB. CaMKII phosphorylates RyR specifically on the site. By 
phosphorylating RyR, CaMKII increases its activity and thus Ca2+ release from the SR (Grimm 
and Brown, 2010). Therefore, in the knockout mouse hearts CaMKII is unable to carry out this 
function so the resulting increase in contractility is not seen.  
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The Pdev was higher in the presence of alpha-AR stimulation in the isolated WT mouse hearts 
when the 10-4 MTX dose was added to the perfusate. Therefore, not only does alpha-AR 
stimulation increase the rate of contraction, it also increases the pressure that the heart can 
develop with each contraction. Again, this was a phenomenon that was not seen in the KO 
mouse hearts, implicating CaMKII as a mediator for the increased developed pressure in 
response to alpha-AR stimulation. The positive effect of CaMKII on contractility of the heart 
was also shown by Daniels et al. (2018), whereby inhibition of CaMKII using KN-93 reduced 
the developed pressure in trabeculae from rat hearts (Daniels et al. 2018). It is unlikely that 
the increase in Pdev is due to an increase in the max pressure reached by the heart since we 
don’t see a significant increase in max pressure in the WT mouse hearts. There is, however, a 
significant change in the min pressure at the highest dose of MTX in the WT hearts.  
4.1.2 Diastolic Function   
The WT mouse hearts were also responsive to the MTX doses when examining functional 
parameters such as Min Pressure, EDP, and Min dP/dT.  
Min pressure reduces significantly when the lowest dose of MTX is added to the perfusate, 
and the min pressure continues to drop with increasing doses of MTX. This shows that the 
min pressure in isolated WT mouse hearts is sensitive to alpha-AR stimulation and that alpha-
adrenergic signalling in the heart may be more involved in the regulation of diastolic function. 
This is reinforced by a similar trend seen in the EDP which shows a statistically significant 
reduction in the WT mouse hearts in response to increasing doses of MTX.  
The reduction in both min pressure and EDP in the WT mouse hearts in response to alpha-AR 
stimulation is a phenomenon that is not seen in the KO mouse hearts. In the absence of 
CaMKII, alpha-AR stimulation does not cause an enhanced relaxation in the heart, implying 
that CaMKII may be causing the reduction in EDP and min pressure in response to alpha-AR 
stimulation. One of the targets of CaMKII that has not been mentioned in this thesis so far is 
the myofilament protein known as Titin. Passive tension in the cardiomyocyte is determined 
by the elastic protein titin, which acts as a spring that recoils during diastole. Phosphorylation 
of titin can alter its stiffness, and thus affect the passive tension in the cardiomyocyte. The 
higher the passive tension, the less relaxed the cardiomyocyte is during diastole. CaMKII has 
been shown to phosphorylate titin and reduce the passive tension in the cardiomyocyte, 
allowing for better relaxation (Hamdani et al. 2013). CaMKII KO models were shown to have 
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a higher passive tension at rest, whereas CaMKII overexpression models had lower passive 
tension compared to their WT counterparts (Hamdani et al 2013).  
The rate of relaxation was significantly faster in the presence of alpha-AR stimulation but only 
at the highest MTX dose in the WT mouse hearts. Thus, alpha-AR stimulation not only 
increases the rate of contraction but also the rate of relaxation. This increase in rate of 
relaxation was not seen in the KO mouse hearts, even at the highest dose of MTX. This implies 
that CaMKII needs to be present for the response to occur, and thus may be a mediator for 
the increased rate of relaxation in a healthy heart. Again, considering the targets of CaMKII in 
the cardiomyocyte, this increased rate of relaxation can be explained by CaMKII 
phosphorylating PLB, which regulates the pump SERCA that is responsible for pumping Ca2+ 
back into the SR after contraction has occurred so that the cardiomyocyte can relax. PLB 
inhibits SERCA and acts as a break on its enzymatic activity. When CaMKII phosphorylates PLB, 
the break is released and SERCA is upregulated, which means that Ca2+ uptake into the SR 
after a contraction is faster. Thus, the cardiomyocyte relaxes faster (Maier et al. 2007).  
4.2 CaMKII KO Animal Model  
4.2.1 Generation of Knockout Model  
The cardiac specific CaMKII-delta knockout mouse model was generated using Cre-LoxP to 
delete the catalytic domain of the CaMKII-delta protein. Embryonic Cells with the gene 
construct were injected into blastocysts that were implanted into mice. The offspring were 
crossed with Pro-Cre mice to produce offspring that had the CaMKII-delta allele with LoxP as 
well as the Pro-Cre allele. The Cre enzyme splices out the segment of DNA that is flanked by 
the LoxP segments. Thus, the catalytic domain of CaMKII delta would be spliced out rendering 
the kinase enzyme non-functional. Heterozygous offspring were crossed with one another 
until homozygous offspring were produced. These were genotyped using tail-tip samples and 
western blots were performed to confirm CaMKII knockout was successful. The western blots 
also showed that there was no compensatory increase in other CaMKII isoforms and that 
there was reduced basal phosphorylation of the CaMKII targets, PLB and RyR at their 
respective CaMKII phosphorylation sites (Ling et al. 2009). All these results establish that the 
knockout was successful.  
4.2.2 Basal Parameters  
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The CaMKII KO model used in these experiments had been developed relatively recently, and 
little is known about their basal function.  The only significant difference I found was between 
the body weights of the two groups. The WT mice weighed significantly more than then KO 
mice. There were no differences expected between the WT and KO mice. Researchers who 
have previously used the KO model have not noticed any significant differences between the 
KO and WT groups with regards to mortality or the presence of physical abnormalities. They 
did not compare the body weight between the two groups but did look at the heart weight 
normalized to the body weight and saw no differences between the two groups in control 
conditions (Ling et al. 2009).  
4.2.3 In-vivo Echocardiography  
There were also no significant structural or functional changes observed on echocardiography 
between the two groups which is consistent with what was previously shown in the literature 
(Ling et al. 2009). This tells us that the knockout of CaMKII did not cause any structural or 
functional abnormalities in the mouse that were detectable, and we can assume that the 
outcomes of the experiments could be attributed directly to the CaMKII protein and not any 
secondary effects caused by the knockout itself.  
4.3 Langendorff Experiment Model  
The Langendorff setup is a complex technique that demands prompt surgical excision and 
cannulation of the heart before excessive deterioration compromises the functionality of the 
heart.  
4.3.1 Optimizing the setup  
The optimal coronary flow and coronary perfusion pressure were obtained from current 
literature, as well as from past mouse Langendorff experiments performed by Jess Calverly 
(PGDipSci, Dept. of Physiology, University of Otago, 2017) and Dr. Rosalind Cook (PhD, Dept. 
of Physiology, University of Otago; previous Research Officer at Baker Heart and Diabetes 
Institute; current Product Specialist at Culpan Medical Pty Ltd.).  
The use of Heparin, an anti-coagulant, was recommended by Dr. Cook prior to opening up the 
thorax for excision of the heart. The heparin preventing micro-clots from blocking the 
coronary circulation when the aorta was cut. Sodium Nitroprusside, a vasodilator, was added 
to the arresting solution so as to maximize exposure of the heart tissue to the arresting 
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solution and, once the heart was cannulated, allowed the perfusing solution to thoroughly 
perfuse all the coronary vessels to wash out and remaining blood. Despite measures taken to 
prevent clots from forming, it is likely that clots would have formed and prevented small areas 
of the myocardium from being perfused, thus compromising cardiac function. The sodium 
nitroprusside was allowed to wash out before alpha-AR stimulation with MTX was carried out, 
thus ensuring that it did not affect the results.  
While the isolated heart setup aims to supply the heart with all the ions, metabolic 
requirements, oxygenation, and pH regulation that is needed for the heart to continue 
beating outside the animal model, it is an artificial setup and deterioration of the heart over 
time is inevitable. Thus, it was important to keep each protocol short enough so that the heart 
was not overly deteriorated by the end of the experiment. But, literature suggests that there 
is a temporal delay before the alpha-AR stimulation showed effects, and the time taken for 
the drug to pass through the Langendorff tubing to reach the heart had to also be accounted 
for. Thus, it was a balance between giving the drug enough time to take effect and also 
ensuring the heart wasn’t hung up for so long that it functionally deteriorated.  
4.3.2 Procedural and technical limitations.   
While I have significant experience in this technique with rat models, adapting it to the much 
smaller mouse model was a challenge. The smaller and more fragile aorta was more difficult 
to identify during the surgical excision of the heart, and differentiating it from the other large 
vessels entering or exiting the heart was a challenge. This meant that a lot of trial and error 
was involved in not only perfecting the technique, but also cannulating the heart within the 
recommended time frame of <5 minutes (Bell 2011). Despite several tries, it was not always 
feasible to cannulate the heart within 5minutes, which means the hearts may have endured 
a small degree of ischemic preconditioning or hypoxic damage, which has the potential to 
affect the function of the heart when it was perfused.  
Another challenge was being able to get the developed pressure to optimal values. The 
pressure developed by the left ventricle was detected with the fluid-filled balloon that was 
inserted into the ventricle through the left atrio-ventricular valve. Dr. Cook also provided, via 
personal communication, the technique used by her to make the smaller balloons. The 
balloons had to be frequently replaced due to their fragile nature, and thus the same balloon 
was not used for all the mouse heart Langendorff experiments. Different balloons of different 
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sizes were used, but the results were still valid as the response to alpha was compared to the 
respective baseline measure of the same heart. However, despite several attempts at 
optimizing the Langendorff, the developed pressure did not reach the expected value of 
100mmHg. It is likely that this was a technical limitation of the mouse Langendorff setup due 
to the small size of the heart. While a balloon with a larger volume may have better detected 
the left ventricular developed pressure, the larger size would have made it harder to insert 
the balloon into the ventricular chamber without significantly damaging the cardiac tissue or 
applying a significant force which would in turn cause the aorta to rip, compromising the 
coronary flow.  
4.3.3 Advantages and disadvantages of Langendorff setup   
 The Langendorff setup is a technically complex procedure but it also allows us to determine 
the effect that a particular protocol or treatment had on the heart itself, without any input 
from endocrine and neuronal systems. It gives a snapshot of the intrinsic function or 
dysfunction of the heart tissue itself, allowing us to better understand the organ in isolation.  
This does not give us a realistic picture of how the organ functions in concert with the rest of 
the body. Mechanisms extrinsic to the heart may compensate for intrinsic dysfunction, such 
as by an increase in the sympathetic “fight or flight” input to the heart to upregulate its 
function. Thus, isolated heart experiments only provide a piece of a much larger puzzle.  
4.4 Clinical Implications and Future Directions  
Understanding CaMKII and its effects in the heart is important because it has been implicated 
in the pathogenesis of many cardiovascular diseases. By better understanding the functional 
effects and its associated signalling pathways, CaMKII can be targeted as a therapy for 
cardiovascular diseases.  
4.4.1 CaMKII and alpha-adrenergic stimulation in diabetic 
cardiomyopathy  
CaMKII has been shown to be activated by oxidative stress and by hyperglycemia, both of 
which are conditions seen in diabetes. Current literature has shown that there is an increased 
amount of phosphorylated and glycated, and therefore activated, CaMKII in diabetic hearts 
compared to non-diabetic hearts (Daniels et al. 2018). It was also shown that the impaired 
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contractility in diabetic hearts was partially restored when CaMKII was inhibited (Daniels et 
al. 2018).  
Diabetes is also a hyperadrenergic state, whereby there is a reduction in the parasympathetic 
activity and an increase in the sympathetic input to the heart (Jia et al. 2018). Increased 
sensitivity to alpha-AR stimulation in diabetic rats was shown by Bussey et al. 2014. While 
diabetic mice were not used in these experiments, it could be beneficial to look at the 
determine whether CaMKII is playing a role in the pathology seen in diabetic cardiomyopathy 
by replicating the experiment in a diabetic mouse model and inhibiting CaMKII, or producing 
a diabetic CaMKII KO mouse and stimulating it with alpha-AR stimulation.  
4.4.2 CaMKII and alpha-adrenergic stimulation in heart failure  
Mouse models that were genetically modified to overexpress CaMKII developed heart failure, 
implicating its role in the pathogenesis of HF. The targets of CaMKII, PLB and RyR, also showed 
an increase in phosphorylation and therefore activation at CaMKII specific phosphorylation 
sites (Zhang et al. 2003). This was further supported by knock-out models that were protected 
from heart failure (Back et al. 2009). Increased CaMKII activity was also shown in failing 
human hearts (Hoch B et al. 1999). Further understanding how CaMKII plays a role in the 
pathogenesis of heart failure can allow us to target it to treat or slow the progression of heart 
failure.  
4.5 Conclusion  
 In this thesis, I aimed to determine whether alpha-adrenergic receptor stimulation had any 
functional effects in the heart and found that it increase systolic parameters such as the rate 
of contraction and the developed pressure, and improved diastolic parameters such as by 
reducing the min pressure and EDP, and increasing the rate of relaxation. All of these 
functional changes were only seen in the healthy wild-type mouse hearts, and were lost in 
the CaMKII knockout mouse hearts, thus implicating CaMKII’s role in mediating these 
functional changes in response to alpha-adrenergic stimulation. CaMKII has been shown to 
be upregulated in diabetic cardiomyopathy and heart failure, and implicated in their 
pathogenesis. Further research into the response to alpha-adrenergic stimulation in these 
disease state, and inhibition or knockout of CaMKII can provide stronger links between the 
alpha adrenergic signalling pathway and the CaMKII activation and signalling pathways, and 




Backs J1, Backs T, Neef S, Kreusser MM, Lehmann LH, Patrick DM, Grueter CE, Qi X, 
Richardson JA, Hill JA, Katus HA, (2009). The delta isoform of CaM kinase II is required 
for pathological cardiac hypertrophy and remodeling after pressure overload. Proc 
Natl Acad Sci U S A.106(7). Pg 2342-7. doi: 10.1073/pnas.0813013106. 
Bayer, K. U., De Koninck, P., & Schulman, H. (2002). Alternative splicing modulates the 
frequency-dependent response of CaMKII to Ca(2+) oscillations. The EMBO 
journal, 21(14). Pg 3590-7. 
Bers DM. (2002) Cardiac excitation-contraction coupling. Nature. 415(6868):198-205 
Bussey CT, de Leeuw AE & Lamberts RR (2014). Increased haemodynamic adrenergic 
load with isoflurane anaesthesia in type 2 diabetic and obese rats in vivo. Cardiovasc 
Diabetol. 13(161) 
Chao LH, Stratton MM, Lee IH, Rosenberg OS, Levitz J, Mandell DJ, Kortemme T, Groves 
JT, Schulman H, Kuriyan J. (2011). A mechanism for tunable autoinhibition in the 
structure of a human Ca2+/calmodulin- dependent kinase II holoenzyme. 
Cell.146(5)pg732-45. doi: 10.1016/j.cell.2011.07.038. 
Chaulet H, Lin F, Guo J, Owens WA, Michalicek J, Kesteven SH, Guan Z, Prall OW, Mearns 
BM, Feneley MP, et al. (2006) Sustained augmentation of cardiac alpha1A-adrenergic 
drive results in pathological remodeling with contractile dysfunction, progressive 
fibrosis and reactivation of matricellular protein genes. J Mol Cell Cardiol. 40. Pg 540–
552 
Chengode S. (2016). Left ventricular global systolic function assessment by 
echocardiography. Annals of cardiac anaesthesia, 19(Supplement).pg S26-S34. 
Chu C, Thai K, Park KW, Wang P, Makwana O, Lovett DH, Simpson PC, and BakerAJ 
(2013) Intraventricular and interventricular cellular heterogeneity of 
inotropicresponses to a(1)-adrenergic stimulation. Am J Physiol Heart Circ Physiol. 
304:H946–H953 
Connell TD, Swigart PM, Rodrigo MC, Ishizaka S, Joho S, Turnbull L, Tecott LH, Baker 
AJ, Foster E, Grossman W, et al. (2006) Alpha1-adrenergic receptors prevent a 
maladaptive cardiac response to pressure overload. J Clin Invest. 116. Pg 1005–1015 
45 
 
Cotecchia S. (2010) The α1-adrenergic receptors: diversity of signaling networks and 
regulation. J Recept Signal Transduct Res. 30:410–419 
Daniels. LJ, Wallace. RS, Nicholson. OM, Wilson. GA, McDonald. FJ, Jones. PP, Baldi. CJ, 
Lamberts. RR and Erickson. JR. (2018). Inhibition of calcium/calmodulin-dependent 
kinase II restores contraction and relaxation in isolated cardiac muscle from type 2 
diabetic rats. Cardiovascular Diabetology.17(1). Pg 89 doi: 10.1186/s12933-018-
0732-x. 
Du XJ, Fang L, Gao XM, Kiriazis H, Feng X, Hotchkin E, Finch AM, Chaulet H, Graham 
RM. (2004) Genetic enhancement of ventricular contractility protects against 
pressure-overload-induced cardiac dysfunction. J Mol Cell Cardiol. 37. Pg 979–987. 
Du XJ, Gao XM, Kiriazis H, Moore XL, Ming Z, Su Y, Finch AM, Hannan RA, Dart AM, 
Graham RM. (2006) Transgenic alpha1A-adrenergic activation limits post-infarct 
ventricular remodeling and dysfunction and improves survival. Cardiovasc Res. 71.pg 
735–743 
Eckel J1, Gerlach-Eskuchen E, Reinauer H.(1991). Alpha-adrenoceptor-mediated 
increase in cytosolic free calcium in isolated cardiac myocytes. J Mol Cell 
Cardiol.23(5):617-25. 
Erickson JR, Pereira L, Wang L, Han G, Ferguson A, Dao K, Copeland RJ, Despa F, Hart 
GW, Ripplinger CM, Bers DM. (2013). Diabetic hyperglycaemia activates CaMKII and 
arrhythmias by O-linked glycosylation. Nature.502(7471):372-6. doi: 
10.1038/nature12537. 
Erickson JR1, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, Bartlett RK, Lowe JS, 
O'Donnell SE, Aykin-Burns N, Zimmerman MC, Zimmerman K, Ham AJ, Weiss RM, 
Spitz DR, Shea MA, Colbran RJ, Mohler PJ, Anderson ME. (2008). A dynamic pathway 
for calcium-independent activation of CaMKII by methionine oxidation. Cell. 133(3). 
Pg 462-74. doi: 10.1016/j.cell.2008.02.048. 
Gray, C. B., & Heller Brown, J. (2014). CaMKIIdelta subtypes: localization and 
function. Frontiers in pharmacology. 5(15). doi:10.3389/fphar.2014.00015 
Grimm M1, Brown JH. (2010). Beta-adrenergic receptor signaling in the heart: role of 
CaMKII. J Mol Cell Cardiol.48(2). Pg 322-30. doi: 10.1016/j.yjmcc.2009.10.016. Epub 
2009 Oct 31. 
46 
 
Grupp IL, Lorenz JN, Walsh RA, Boivin GP, Rindt H. (1998) Overexpression of alpha1B-
adrenergic receptor induces left ventricular dysfunction in the absence of 
hypertrophy. Am J Physiol. 275. Pg H1338–H1350 
Hamdani N, Krysiak J, Kreusser MM, Neef S, Dos Remedios CG, Maier LS, Krüger M, 
Backs J, Linke WA. (2013). Crucial role for Ca2(+)/calmodulin-dependent protein 
kinase-II in regulating diastolic stress of normal and failing hearts via titin 
phosphorylation. Circ Res.112(4). Pg 664-74. doi: 10.1161/CIRCRESAHA.111.300105. 
Hoch B, Meyer R, Hetzer R, Krause EG, Karczewski P. (1999). Identification and 
expression of delta-isoforms of the multifunctional Ca2+/calmodulin-dependent 
protein kinase in failing and nonfailing human myocardium. Circ Res. 84(6). Pg 713-
21. 
Huang Y, Wright CD, Kobayashi S, Healy CL, Elgethun M, Cypher A, Liang Q, O'Connell 
TD. (2008) GATA4 is a survival factor in adult cardiac myocytes but is not required 
for {alpha}1A-adrenergic receptor survival signaling. Am J Physiol. 295. Pg H699–
H707 
Huang Y, Wright CD, Merkwan CL, Baye NL, Liang Q, Simpson PC, O’Connell TD. 
(2007) An alpha1A-adrenergic-extracellular signal-regulated kinase survival 
signaling pathway in cardiac myocytes. Circulation. 115. Pg 763–772 
Hudmon A, Schulman H. (2002) Structure-function of the multifunctional 
Ca2+/calmodulin-dependent protein kinase II. Biochem J.364(3):593-611 
Iaccarino G, Keys JR, Rapacciuolo A, Shotwell KF, Lefkowitz RJ, Rockman HA, Koch WJ. 
(2001) Regulation of myocardial betaARK1 expression in catecholamine-induced 
cardiac hypertrophy in transgenic mice overexpressing alpha1B-adrenergic 
receptors. J Am Coll Cardiol. 38. Pg 534–540 
Jensen BC, Swigart PM, Simpson PC. (2009c) Ten commercial antibodies for alpha-1-
adrenergic receptor subtypes are nonspecific. Naunyn Schmiedebergs Arch 
Pharmacol. 379:409–412 
Jia G, Hill MA1, Sowers JR2. (2018). Diabetic Cardiomyopathy: An Update of 




Kaese, S., & Verheule, S. (2012). Cardiac electrophysiology in mice: a matter of 
size. Frontiers in physiology.3( 45). doi:10.3389/fphys.2012.00345 
Kohlhaas M, Zhang T, Seidler T, Zibrova D, Dybkova N, Steen A, Wagner S, Chen L, 
Brown JH, Bers DM, Maier LS. Increased sarcoplasmic reticulum calcium leak but 
unaltered contractility by acute CaMKII overexpression in isolated rabbit cardiac 
myocytes. Circ Res. 98.pg 235–244. 
Lars S. Maier, Donald M. Bers, Joan Heller Brown. (2007). Calmodulin and 
Ca2+/calmodulin kinases in the heart – Physiology and 
pathophysiology. Cardiovascular Research. 73( 4). Pg 629–
630, https://doi.org/10.1016/j.cardiores.2007.01.005 
Lemire I, Ducharme A, Tardif JC, Poulin F, Jones LR, Allen BG, Hébert TE, Rindt H. 
(2001) Cardiac-directed overexpression of wild-type alpha1B-adrenergic receptor 
induces dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 281. Pg H931–H938 
Lin F, Owens WA, Chen S, Stevens ME, Kesteven S, Arthur JF, Woodcock EA, Feneley 
MP, Graham RM. (2001) Targeted alpha(1A)-adrenergic receptor overexpression 
induces enhanced cardiac contractility but not hypertrophy. Circ Res. 89.343–350 
Ling H, Gray CB, Zambon AC, Grimm M, Gu Y, Dalton N, Purcell NH, Peterson K, Brown 
JH. (2013). Ca2+/Calmodulin-dependent protein kinase II δ mediates myocardial 
ischemia/reperfusion injury through nuclear factor-κB. Circ Res.112(6). Pg 935-44. 
doi: 10.1161/CIRCRESAHA.112.276915. 
Ling H, Zhang T, Pereira L, Means CK, Cheng H, Gu Y, Dalton ND, Peterson KL, Chen J, 
Bers D, Brown JH. (2009). Requirement for Ca2+/calmodulin-dependent kinase II in 
the transition from pressure overload-induced cardiac hypertrophy to heart failure in 
mice. J Clin Invest. 119(5). Pg 1230-40. doi: 10.1172/JCI38022. Bell, R. M., et al. (2011). 
Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. J 
Mol Cell Cardiol 50(6): 940-950. 
Ministry of Health (2015) NZ Health Survey: Annual update of key results 2014-2015. 
Wellington: Ministry of Health 
Mollova, M. Y., Katus, H. A., & Backs, J. (2015). Regulation of CaMKII signaling in 




Noguchi H, Muraoka R, Kigoshi S, Muramatsu I. (1995) Pharmacological 
characterization of alpha 1-adrenoceptor subtypes in rat heart: a binding study. Br J 
Pharmacol. 114:1026–1030 
Norton JM. (2001). TOWARD CONSISTENT DEFINITIONS FOR PRELOAD AND 
AFTERLOAD. American Physiological Society. 25(1). Pg 53-
61.https://doi.org/10.1152/advances.2001.25.1.53 
O-Uchi J1, Sasaki H, Morimoto S, Kusakari Y, Shinji H, Obata T, Hongo K, Komukai K, 
Kurihara S.(2008). Interaction of alpha1-adrenoceptor subtypes with different G 
proteins induces opposite effects on cardiac L-type Ca2+ channel. Circ 
Res.102(11):1378-88. doi: 10.1161/CIRCRESAHA.107.167734. 
Rokosh DG, Simpson PC. (2002) Knockout of the alpha 1A/C-adrenergic receptor 
subtype: the alpha 1A/C is expressed in resistance arteries and is required to maintain 
arterial blood pressure. Proc Natl Acad Sci USA. 99. pg 9474–9479 
Ross SA, Rorabaugh BR, Chalothorn D, Yun J, Gonzalez-Cabrera PJ, McCune DF, Piascik 
MT, Perez DM. (2003). The alpha(1B)-adrenergic receptor decreases the inotropic 
response in the mouse Langendorff heart model. Cardiovasc Res. 60(3):598-607. 
Schworer CM, Rothblum LI, Thekkumkara TJ, Singer HA. Identification of novel 
isoforms of the delta subunit of Ca2+/calmodulin-dependent protein kinase II. 
Differential expression in rat brain and aorta. Journal of Biological Chemistry. 268. Pg 
14443–14449. 
Toko, H., Takahashi, H., Kayama, Y., Oka, T., Minamino, T., Okada, S., Morimoto, S., Zhan, 
D. Y., Terasaki, F., Anderson, M. E., Inoue, M., Yao, A., Nagai, R., Kitaura, Y., Sasaguri, T., 
… Komuro, I. (2010). Ca2+/calmodulin-dependent kinase IIdelta causes heart failure 
by accumulation of p53 in dilated cardiomyopathy. Circulation. 122(9).pg 891-9. 
Vecchione C, Fratta L, Rizzoni D, Notte A, Poulet R, Porteri E, Frati G, Guelfi D, Trimarco 
V, Mulvany MJ, et al. (2002) Cardiovascular influences of alpha1b-adrenergic receptor 
defect in mice. Circulation. 105. Pg 1700–1707 
Wang BH, Du XJ, Autelitano DJ, Milano CA, Woodcock EA. (2000) Adverse effects of 
constitutively active alpha(1B)-adrenergic receptors after pressure overload in 
mouse hearts. Am J Physiol Heart Circ Physiol. 279. Pg H1079–H108 
49 
 
Wang GY, McCloskey DT, Turcato S, Swigart PM, Simpson PC, Baker AJ. (2006). 
Contrasting inotropic responses to alpha1-adrenergic receptor stimulation in left 
versus right ventricular myocardium. Am J Physiol Heart Circ Physiol. 291(4):H2013-
7. 
Wright CD, Chen Q, Baye NL, Huang Y, Healy CL, Kasinathan S, O’Connell TD. 
(2008) Nuclear alpha1-adrenergic receptors signal activated ERK localization to 
caveolae in adult cardiac myocytes. Circ Res. 103:992–1000 
Zhang T, Maier LS, Dalton ND, Miyamoto S, Ross J Jr, Bers DM, Brown JH. (2003). The 
deltaC isoform of CaMKII is activated in cardiac hypertrophy and induces dilated 
cardiomyopathy and heart failure. Circ Res.92(8). Pg 912-9. 
Zhang T1, Kohlhaas M, Backs J, Mishra S, Phillips W, Dybkova N, Chang S, Ling H, Bers 
DM, Maier LS, Olson EN, Brown JH.(2007). CaMKIIdelta isoforms differentially affect 
calcium handling but similarly regulate HDAC/MEF2 transcriptional responses. Biol 
Chem.282(48). Pg 35078-87. 
Zhu H, McElwee-Witmer S, Perrone M, Clark KL, Zilberstein A. (2000) Phenylephrine 
protects neonatal rat cardiomyocytes from hypoxia and serum deprivation-induced 
apoptosis. Cell Death Differ. 7. pg 773–784 
Zwart R, Verhaagh S, Buitelaar M, Popp-Snijders C, Barlow DP. (2001) Impaired 
activity of the extraneuronal monoamine transporter system known as uptake-2 in 
Orct3/Slc22a3-deficient mice. Mol Cell Biol. 21:4188–4196 
 
